Bauer, J., Köhler, N., Zwick, M., Dicks, S., Börries, M. und Walz, J.S. (2022) The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma [cd]. Freiburg: Universität. doi:10.1038/s41467-022-33746-3.
Chicago Manual of Style 17th edition (full note)Bauer, Jens, Natalie Köhler, Melissa Zwick, Severin Dicks, Melanie Börries, und Juliane S. Walz. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Cd. Freiburg: Universität, [2022?], Freiburg: Universität, [2022?]. https://doi.org/10.1038/s41467-022-33746-3.
American Psychological Association 7th editionBauer, J., Köhler, N., Zwick, M., Dicks, S., Börries, M., & Walz, J. S. (ca. 2022). The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma [Cd]. Universität. https://doi.org/10.1038/s41467-022-33746-3
Modern Language Association 9th editionBauer, J., N. Köhler, M. Zwick, S. Dicks, M. Börries, und J. S. Walz. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. cd, Universität, 2022, https://doi.org/10.1038/s41467-022-33746-3.
ISO-690 (author-date, Deutsch)BAUER, Jens, Natalie KÖHLER, Melissa ZWICK, Severin DICKS, Melanie BÖRRIES und Juliane S. WALZ, 2022. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Freiburg: Universität